UTMD

Business Context and Reporting Period

Company: Utah Medical Products, Inc. (UTMD)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2025
Business Overview: UTMD manufactures and markets specialty medical devices, including gynecology/electrosurgery, labor & delivery, neonatal critical care, and blood pressure monitoring products. The company operates as a single segment with manufacturing and sales facilities in the U.S., Ireland, UK, Australia, and Canada.

Key Financial Metrics

Note: All figures in thousands except per share amounts and percentages.

Material Changes vs. Prior Period

• Revenue Decline: Net sales decreased 1.9% in Q3 and 7.2% in the first nine months of 2025 compared to the prior year. This was driven by a 13.3% drop in Outside U.S. (OUS) sales and a significant decline in OEM sales to a major customer (PendoTECH).
• Unusual Items: Q3 2025 results were negatively impacted by the cancellation of "non-changeable" orders by two OUS distributors, resulting in a $581 revenue loss and a $395 bad debt reserve charge. Additionally, U.S. tariffs on imported Filshie devices increased costs by $78 in Q3.
• Margin Compression: Gross and operating margins declined due to lower sales volume (reducing fixed cost absorption), higher operating expenses (including the bad debt charge), and tariff-related costs.
• Shareholder Returns: The company repurchased 130,984 shares for $7,361 in the first nine months of 2025 and paid $3,006 in dividends.

Guidance, Outlook, and Risks

• Full Year 2025 Outlook: Management revised its full-year sales guidance to expect a 6-7% decline compared to 2024 (previously projected at 5%). Full-year EPS is now expected to be in the range of $3.40 to $3.50.
• Key Risks:
  • Trade & Tariffs: Reciprocal tariffs and trade events have led to order cancellations and increased costs for imported components.
  • Customer Concentration: Continued decline in sales to major OEM customer PendoTECH, though management believes this trend has "almost bottomed out."
  • Foreign Exchange: Fluctuations in EUR, GBP, AUD, and CAD impact reported revenues and expenses, though a stronger USD generally mitigates some foreign currency gains.
  • Litigation: Ongoing product liability litigation regarding the Filshie Clip System, though management does not expect a material impact on consolidated results.
• Management Commentary: Despite revenue contraction, the company maintains strong liquidity and profitability. Management plans to continue opportunistic share repurchases and dividends while seeking accretive acquisition opportunities.

Investor Verification Checklist

• Distributor Cancellations: Verify the status of the $395 bad debt reserve related to the China distributor and the likelihood of recovering the cancellation fee.
• OEM Recovery: Monitor the trajectory of sales to PendoTECH to confirm if the decline has truly stabilized as management suggests.
• Tariff Impact: Assess the long-term effect of the 15% U.S. tariff on Irish-manufactured Filshie devices on gross margins and pricing power.
• Amortization End Date: Note that the significant Femcare IIA amortization expense (approx. 5% of revenue) is scheduled to end in Q1 2026, which should improve future operating margins.
• Cash Position: Confirm the sustainability of the dividend and buyback program given the projected 7% revenue decline for the full year.